Abstract:Background: Cytosolic phospholipase A2α (cPLA2α) is the key enzyme that initiates the arachidonic acid cascade through which proinflammatory lipid mediators can be formed. Therefore, cPLA2α is considered an interesting target for the development of anti-inflammatory drugs. Although several effective inhibitors of the enzyme have been developed, none of them has yet reached clinical application. Objective: Recently, we have prepared new 4-sulfamoylbenzoic acid derivatives based on a cPLA2α inhibitor found in a ligand-based virtual screening. The most effective of these compounds were now subjected to further variations in which the substitution pattern on the sulfamoyl nitrogen atom was changed. Methods: The new compounds were tested in vitro in a vesicle assay for cPLA2α inhibition as well as for their water solubility, metabolic stability, and selectivity towards related enzymes. In addition, they were evaluated ex vivo in a whole blood assay in which metabolites of the arachidonic acid cascade formed after activation of cPLA2α were quantified using a combined online dilution/online solid phase extraction HPLC-MS method. Results: Inhibitors with submicromolar inhibitory in vitro potency were found with favourable water solubility and selectivity. However, their efficacy did not match that of the highly effective, known, structurally related cPLA2a inhibitor giripladib, which was also tested as a reference. One advantage of some of the new compounds compared to giripladib was their significantly improved water solubility. When analyzing the substances in the ex vivo whole blood assay, it was found that the obtained inhibition data correlated better with the in vivo results when the phorbol ester 12-Otetradecanoylphorbol-13-acetate was used for activation of the enzyme in the blood cells instead of the calcium ionophore A23187. Conclusion: New compounds with good activity towards cPLA2α and reasonable physicochemical properties were identified. Overall, the results obtained could be helpful in the development of clinically applicable inhibitors of this enzyme.

Improved synthesis of darapladib,a lipoprotein-associated phospholipase A_2 inhibitor

Glycyrrhizic Acid-Phospholipid Complex: Preparation Process Optimization and Therapeutic and Pharmacokinetic Evaluation in Rats

Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A2 by detergent micelles or lipoproteins and for the efficacy reduction of darapladib

Use of Lipase Catalytic Resolution in the Preparation of Ethyl (2S,5r)-5-((benzyloxy)amino)piperidine-2-carboxylate, a Key Intermediate of the Β-Lactamase Inhibitor Avibactam

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Synthesis of a New Antihyperlipidaemic Agent-Simvastatin

Supramolecularly Engineered Phospholipids Constructed by Nucleobase Molecular Recognition: Upgraded Generation of Phospholipids for Drug Delivery.

[Improved Synthesis Process of Diethyl N-[4-[(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)methylamino]benzoyl]-L-glutamate].

New Synthesis Process for the Synthesis of Ezetimibe

Efficient synthesis of D-pantolactone in monophase and organic-aqueous biphase reaction biosystem using a novel conjugated polyketide reductase based on integrated substrate pocket alteration

Discovery of novel chromone and acrylate‐based pancreatic lipase inhibitors: Molecular modelling, synthesis, and in vitro evaluation for the treatment of obesity

Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib

A facile synthesis of 2-(4-((4-chlorophenyl)(hydroxy)methyl) phenoxy)-2-methylpropanoic acid: Metabolite of anti-hyperlipidemic drug Fenofibrate

Synthetic technology of N6-benzoyl-2′-O-tert-butyldimethylsilyl-adenosine-3′-yl-H-phosphonate

An improved synthetic strategy for the multigram-scale synthesis of DNA–PK inhibitor AZD7648

Development of an improved and facile synthesis route of the FGFR inhibitor erdafitinib

N,N-Disubstituted 4-sulfamoylbenzoic Cid Derivatives as Inhibitors of Cytosolic Phospholipase A2α: Synthesis, Aqueous Solubility, and Activity in a Vesicle and a Whole Blood Assay

An improved synthesis of captopril intermediate

Chenodeoxycholic Acid‐Modified Polyethyleneimine Nano‐Composites Deliver Low‐Density Lipoprotein Receptor Genes for Lipid‐Lowering Therapy by Targeting the Liver

Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy

Phospholipase D-Catalyzed Transphosphatidylation for the Synthesis of Rare Complex Phospholipid Species─Hemi-bis(monoacylglycero)phosphate and Bis(diacylglycero)phosphate